Today: 29 April 2026
Browse Category

NASDAQ:BHVN 14 August 2025 - 5 November 2025

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven Ltd. shares plunged about 40% on Nov. 5, 2025, after the FDA rejected its lead drug VYGLXIA for spinocerebellar ataxia, citing trial design and data issues. The company will cut R&D spending by 60% and halt non-priority programs. Analysts downgraded the stock, which now trades near $8–9, down over 70% year-over-year. Biohaven reported a $198 million net loss in Q2 with $408 million in cash.
5 November 2025
·
Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

The FDA approved Insmed’s brensocatib as the first therapy for non-cystic fibrosis bronchiectasis, following positive results in a 1,700-patient trial. Novartis reported Phase 3 successes for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. In China, RemeGen’s telitacicept met its main goal in a Phase 3 Sjögren’s trial. Response Pharmaceuticals’ RDX-002 showed weight-loss maintenance in post-GLP-1 patients.
14 August 2025
···

Stock Market Today

  • Tuya (TUYA) Stock Analysis: Fair Pricing Amid Recent Pullback and Strong Long-Term Gains
    April 29, 2026, 12:05 PM EDT. Tuya (NYSE:TUYA) shares closed at $2.28, down 3.0% in one day and 6.2% over seven days, contrasting with a 3-year total shareholder return of 28.7%. The company reported $321.8 million in annual revenue and $57.9 million net income. Trading at a price-to-earnings (P/E) ratio of 24.1x, Tuya's valuation is slightly above its fair value estimate of 23.5x and peers' average of 21.7x, but below the broader U.S. Software industry average of 30.4x. This reflects investor confidence in its profitability and growth prospects, with earnings expected to grow nearly 10% annually. Risks include dependence on Chinese market demand and relatively rich valuation compared to peers. The stock trades just 0.9% below its intrinsic value according to discounted cash flow (DCF) estimates, suggesting near fair pricing.

Latest article

Mastercard Stock Jumps Before Earnings as Visa’s Big Beat Sends a Fresh Signal

Mastercard Stock Jumps Before Earnings as Visa’s Big Beat Sends a Fresh Signal

29 April 2026
Purchase, New York, April 29, 2026, 12:06 EDT Mastercard shares rose 3.8% to $526.90 in late Wednesday morning trading, as investors marked up payment networks after Visa beat profit estimates and raised its full-year earnings outlook a day before Mastercard reports its own quarter. Visa shares were up 8.7%, while American Express was little changed. (Reuters) The move matters because Mastercard’s Thursday report will give investors another quick read on whether card spending is still holding up despite higher costs, war-driven travel disruption and broader market caution. Mastercard said it will release first-quarter results on April 30 and hold a
GE HealthCare Technologies Inc. Stock Sinks as Tariffs and Chip Costs Force Profit Cut

GE HealthCare Technologies Inc. Stock Sinks as Tariffs and Chip Costs Force Profit Cut

29 April 2026
GE HealthCare cut its 2026 profit forecast Wednesday, citing higher chip, oil, and freight costs, as well as tariffs and a supplier issue. Shares fell nearly 13% to $59.75. First-quarter revenue rose 7.4% to $5.13 billion, but net income dropped to $389 million from $564 million a year earlier. The company also announced a reorganization, merging its Imaging and Advanced Visualization units.
Applied Materials (AMAT) Faces Fresh China Shock After U.S. Targets Hua Hong Shipments

Applied Materials (AMAT) Faces Fresh China Shock After U.S. Targets Hua Hong Shipments

29 April 2026
The U.S. Commerce Department ordered Applied Materials, Lam Research, and KLA to halt some chip-tool shipments to China’s Hua Hong, Reuters reported. The move targets shipments linked to facilities believed capable of advanced chip production. Applied reported $2.10 billion in China revenue last quarter, or 30% of its total. Shares in Applied, Lam, and KLA traded lower after the news.
Go toTop